PCVX: 8-K company filing

pcvx-20260615 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _____________________________________________ FORM 8-K _____________________________________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2026 _____________________________________________ Vaxcyte, Inc. (Exact name of Registrant as Specified in Its Charter) _____________________________________________ Delaware 01-39323 46-4233385 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 825 Industrial Road Suite 300 San Carlos , California 94070 (Address of Principal Executive Offices) (Zip Code) Registrant’s Telephone Number, Including Area Code: ( 650 ) 837-0111 Not Applicable (Former Name or Former Address, if Changed Since Last Report) _____________________________________________ Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.001 par value per share PCVX The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in